Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Free Cash Flow (2017 - 2025)

Puma Biotechnology's Free Cash Flow history spans 9 years, with the latest figure at $14.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 7.2% year-over-year to $14.5 million; the TTM value through Dec 2025 reached $41.8 million, up 7.39%, while the annual FY2025 figure was $41.8 million, 7.39% up from the prior year.
  • Free Cash Flow reached $14.5 million in Q4 2025 per PBYI's latest filing, up from $9.7 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $17.3 million in Q3 2022 to a low of -$26.9 million in Q1 2022.
  • Average Free Cash Flow over 5 years is $5.6 million, with a median of $10.1 million recorded in 2023.
  • Peak YoY movement for Free Cash Flow: crashed 18648.65% in 2022, then skyrocketed 1297.62% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at -$5.4 million in 2021, then surged by 241.36% to $7.7 million in 2022, then skyrocketed by 35.74% to $10.4 million in 2023, then skyrocketed by 49.84% to $15.6 million in 2024, then dropped by 7.2% to $14.5 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Free Cash Flow are $14.5 million (Q4 2025), $9.7 million (Q3 2025), and $14.1 million (Q2 2025).